

# Synthesis and biological capacity of *N*-substituted alkyl benzeneselenazolones and diselenides

Agata Joanna Pacuła<sup>1</sup>, Jacek Ścianowski<sup>1\*</sup>, Katarzyna Kaczor<sup>2</sup>,  
Jędrzej Antosiewicz<sup>2</sup>

<sup>1</sup>*Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University,  
7 Gagarin Street, 87-100 Torun, Poland, [jsch@chem.umk.pl](mailto:jsch@chem.umk.pl)*


<sup>2</sup>*Department of Bioenergetics and Physiology of Exercise, Medical University of Gdansk,  
1 Debinki Street, 80-211 Gdansk, Poland*

**Abstract:** *N*-Substituted benzeneselenazol-3(2*H*)-ones are well known for their ability to mimic the activity of an important antioxidant enzyme glutathione peroxidase. They eliminate the excess of reactive oxygen and nitrogen species and restore the cells redox homeostasis. In the catalytic cycle they can be easily transformed to diselenides, which also exhibit these unique properties. In this work, we have synthesized a series of *N*-alkyl benzeneselenazolones and corresponding diselenides. The antioxidant activity of all obtained compounds was evaluated and compared. The connection between the antioxidant properties and the ability to inhibit cancer cells proliferation was evaluated by a cytotoxic activity assay using PC-3 and DU145 cell lines.

**Keywords:** benzeneselenazolones, diselenides, antioxidant and anticancer activity

## Introduction

The pharmacological potential of benzeneselenazolones is mainly associated with their antioxidant properties. This feature is based on the ability of organoselenium compounds to mimic the activity of glutathione peroxidase, an enzyme responsible for maintaining the redox balance in the human body. First discovery, in the early 80's, that ebselen (*N*-phenylbenzeneselenazol-3(2*H*)-one) inhibits generation of reactive oxygen species, cleared the way for a broader research elucidating the application of organoselenium compounds in oxidative stress induced diseases. This includes cancer prevention, anti-Alzheimer and anti-Parkinson therapeutics and also cardiovascular drugs and therapy [1-3]. In the catalytic cycle hydrogen peroxide can be eliminated, in the presence of endogenous thiols, by ebselen **1** or by the corresponding diselenide **2** which are further transformed to selenenic acid **3** and regenerated by the elimination of a water molecule (Scheme 1)[4].




**Scheme 1.** Catalytic elimination of peroxides by ebselen **1** and diselenide **2**

In this communication we present the evaluation of the antioxidant capacity of a series of newly synthesized *N*-alkyl benzoselenazol-3(2*H*)-ones and corresponding diselenides. As oxidative stress is highly connected with carcinogenesis the anticancer activity of selected, most potent derivative is also presented.


## Results and discussion

In the methodology developed in our research group benzoselenazolone **4** was synthesized from appropriate *o*-iodobenzamide in the reaction with lithium diselenide formed *in situ* from lithium hydroxide and selenium in the presence of hydrazine hydrate. Compound **4** was then transformed to the corresponding diselenide **5** by reduction with sodium borohydride, then oxidation (Scheme 2) [5].




**Scheme 2.** Synthesis of ebselen derivatives and corresponding diselenides

By applying this method we were able to synthesis a series of *N*-alkyl benzisoselenazol-3(2H)-ones and diselenides in moderate to high yields (57-98%) (Scheme 3).



**Scheme 3.** Synthesized *N*-alkyl derivatives


The ability to eliminate peroxides was tested by a NMR assay were dithiol **6** is transformed by a selenocatalyst, in the presence of hydrogen peroxide, to a disulphide **7**. The rate of the reaction is measured from the changes in the <sup>1</sup>H NMR spectrum (Table 1) [6].



Catalyst [0.1 equiv.]	Substrate concentration [%]				
	3 min	5 min	15 min	30 min	60 min
<b>4a</b>	78	65	35	11	0
<b>5a</b>	96	94	90	85	77
<b>4b</b>	81	59	41	32	29
<b>5b</b>	93	88	82	77	73
<b>4c</b>	76	69	58	53	41
<b>5c</b>	59	36	12	0	0
<b>4d</b>	77	58	42	28	13
<b>5d</b>	65	49	38	31	21
<b>4e</b>	75	69	62	55	44
<b>5e</b>	92	85	75	65	54
<b>Ebselen</b>	84	75	64	58	52

**Table 1.** Activity of the tested catalysts

Benzisoselenazolones exhibited higher activity than corresponding diselenides, only in the case of *N*-allyl derivatives better result was obtained for the diselenide **5c** which was additionally the most active compound. To analyze if the high antioxidant potential can be related to anticancer properties compound **5c** was also tested as a cytotoxic agent using prostate cancer cell lines with genetic background (PC-3, DU145). The cytotoxicity and inhibition of cell proliferation were identified by Sulforhodamine B assay (SRB), 24h treatment with different concentrations of compound **5c** (\*\*  $p < 0,001$ , \*  $p < 0,01$  significant differences versus control) (Figure 1).



**Figure 1.** Effect of *N*-allyl diselenide on DU 145 and PC-3 cancer cells, determined by SRB assay

## Conclusion

A series of *N*-alkyl benzisoselenazolones have been synthesized and further easily transformed into corresponding diselenides. On the basis of the high peroxide-scavenging properties of ebselen evaluation of the antioxidant activity of all synthesized compounds has been performed. Best results were obtained for *N*-allyl diselenide **5c**. Compound **5c** was also tested as an anticancer agent and resulted to possess high antioxidant and antiproliferative activity against prostate cancer cell lines.

## References

- [1] Valko, M.; Leibfritz, D.; Moncol, J.; Cronin M.T.D.; Mazur, M.; Telser, J. *J. of Biochem. & Cell Biol.* **2007**, *39*, 44-84.
- [2] Weekley, C. M.; Harris, H. H. *Chem. Soc. Rev.* **2013**, *42*, 8870-8894.
- [3] Parnham, J. M.; Sies, H. *Biochem. Pharm.* **2013**, *86*, 1248-1253.
- [4] Bhujan, B.J.; Mugesh, G. *Biological and Biochemical Aspects of Selenium Compounds in Organoselenium Chemistry*, Wirth, T. (ed.) WILEY-VCH; Weinheim, **2012**.
- [5] Pacuła, A. J.; Ścianowski, J.; Aleksandrak, K. B. *RSC Adv.* **2014**, *4*, 48959-48962.
- [6] Kumakura, F.; Mishra, B.; Priyadarsini, K. I.; Iwaoka, M. *Eur. J. Org. Chem.*, **2010**, 440-445.